Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Aug;68(2):403–406. doi: 10.1038/bjc.1993.349

Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.

V Hird 1, A Maraveyas 1, D Snook 1, B Dhokia 1, W P Soutter 1, C Meares 1, J S Stewart 1, P Mason 1, H E Lambert 1, A A Epenetos 1
PMCID: PMC1968585  PMID: 8347497

Abstract

Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled monoclonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as part of an extended phase I-II trial. The treatment was well tolerated and the only significant toxicity observed was reversible myelosuppression as previously described. Following conventional surgery and chemotherapy, 21 out of the 52 patients had no evidence of residual disease and were regarded as receiving treatment in an adjuvant setting. To date, two of these patients have died of their disease (follow-up 3-62 months, median follow-up 35 months). This extended phase I-II study suggests that patients with advanced ovarian cancer who achieve a complete remission following conventional therapy may benefit from further treatment with intraperitoneal radioactive monoclonal antibody.

Full text

PDF
406

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antibody-guided irradiation of malignant lesions: three cases illustrating a new method of treatment. A report from the Hammersmith Oncology Group and the Imperial Cancer Research Fund. Lancet. 1984 Jun 30;1(8392):1441–1443. [PubMed] [Google Scholar]
  2. Arklie J., Taylor-Papadimitrious J., Bodmer W., Egan M., Millis R. Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers. Int J Cancer. 1981 Jul 15;28(1):23–29. doi: 10.1002/ijc.2910280105. [DOI] [PubMed] [Google Scholar]
  3. Bast R. C., Jr, Knauf S., Epenetos A., Dhokia B., Daly L., Tanner M., Soper J., Creasman W., Gall S., Knapp R. C. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer. 1991 Oct 15;68(8):1758–1763. doi: 10.1002/1097-0142(19911015)68:8<1758::aid-cncr2820680819>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  4. Borrebaeck C. A., Danielsson L., Möller S. A. Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes. Proc Natl Acad Sci U S A. 1988 Jun;85(11):3995–3999. doi: 10.1073/pnas.85.11.3995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Colcher D., Zalutsky M., Kaplan W., Kufe D., Austin F., Schlom J. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res. 1983 Feb;43(2):736–742. [PubMed] [Google Scholar]
  6. Courtenay-Luck N. S., Epenetos A. A., Sivolapenko G. B., Larche M., Barkans J. R., Ritter M. A. Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet. 1988 Oct 15;2(8616):894–897. doi: 10.1016/s0140-6736(88)92482-8. [DOI] [PubMed] [Google Scholar]
  7. Epenetos A. A., Britton K. E., Mather S., Shepherd J., Granowska M., Taylor-Papadimitriou J., Nimmon C. C., Durbin H., Hawkins L. R., Malpas J. S. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet. 1982 Nov 6;2(8306):999–1005. doi: 10.1016/s0140-6736(82)90046-0. [DOI] [PubMed] [Google Scholar]
  8. Epenetos A. A., Munro A. J., Stewart S., Rampling R., Lambert H. E., McKenzie C. G., Soutter P., Rahemtulla A., Hooker G., Sivolapenko G. B. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol. 1987 Dec;5(12):1890–1899. doi: 10.1200/JCO.1987.5.12.1890. [DOI] [PubMed] [Google Scholar]
  9. Gendler S. J., Burchell J. M., Duhig T., Lamport D., White R., Parker M., Taylor-Papadimitriou J. Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci U S A. 1987 Sep;84(17):6060–6064. doi: 10.1073/pnas.84.17.6060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kosmas C., Epenetos A. A., Courtenay-Luck N. S. Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. Br J Cancer. 1991 Sep;64(3):494–500. doi: 10.1038/bjc.1991.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kosmas C., Snook D., Gooden C. S., Courtenay-Luck N. S., McCall M. J., Meares C. F., Epenetos A. A. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res. 1992 Feb 15;52(4):904–911. [PubMed] [Google Scholar]
  12. Larson S. M., Carrasquillo J. A., Colcher D. C., Yokoyama K., Reynolds J. C., Bacharach S. A., Raubitchek A., Pace L., Finn R. D., Rotman M. Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. J Nucl Med. 1991 Sep;32(9):1661–1667. [PubMed] [Google Scholar]
  13. LoBuglio A. F., Wheeler R. H., Trang J., Haynes A., Rogers K., Harvey E. B., Sun L., Ghrayeb J., Khazaeli M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220–4224. doi: 10.1073/pnas.86.11.4220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Marsoni S., Torri V., Valsecchi M. G., Belloni C., Bianchi U., Bolis G., Bonazzi C., Colombo N., Epis A., Favalli G. Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). Br J Cancer. 1990 Sep;62(3):444–450. doi: 10.1038/bjc.1990.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Meares C. F., Moi M. K., Diril H., Kukis D. L., McCall M. J., Deshpande S. V., DeNardo S. J., Snook D., Epenetos A. A. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl. 1990 Jul;10:21–26. [PMC free article] [PubMed] [Google Scholar]
  16. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Vriesendorp R., Kooyman C. D., van Lindert A. C., Hamerlynck J. V., van Lent M., van Houwelingen J. C. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet. 1984 Sep 15;2(8403):594–600. doi: 10.1016/s0140-6736(84)90594-4. [DOI] [PubMed] [Google Scholar]
  17. Pateisky N., Philipp K., Skodler W. D., Czerwenka K., Hamilton G., Burchell J. Radioimmunodetection in patients with suspected ovarian cancer. J Nucl Med. 1985 Dec;26(12):1369–1376. [PubMed] [Google Scholar]
  18. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 1988 Mar 24;332(6162):323–327. doi: 10.1038/332323a0. [DOI] [PubMed] [Google Scholar]
  19. Stewart J. S., Hird V., Snook D., Dhokia B., Sivolapenko G., Hooker G., Papadimitriou J. T., Rowlinson G., Sullivan M., Lambert H. E. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol. 1990 Dec;8(12):1941–1950. doi: 10.1200/JCO.1990.8.12.1941. [DOI] [PubMed] [Google Scholar]
  20. Stewart J. S., Hird V., Snook D., Sullivan M., Hooker G., Courtenay-Luck N., Sivolapenko G., Griffiths M., Myers M. J., Lambert H. E. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):405–413. doi: 10.1016/0360-3016(89)90337-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES